J. Grenier

发表

Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial

G. Romieu, O. Trédan, V. D’Hondt, 2020, Nutrients.

Molecular prognostic factors in resectable non-small cell lung cancer.

J. Soria, T. le Chevalier, P. Vielh, 2005, Critical reviews in oncology/hematology.

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer

F. Bertucci, T. Petit, J. Pierga, 2020, Frontiers in Oncology.

Risk factors for brain relapse in patients with metastatic breast cancer.

F. André, A. Dunant, M. Spielmann, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial†

G. MacGrogan, F. Bidard, O. Trédan, 2016 .

LBA9Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2017 .

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.

I. Bièche, F. Clatot, F. André, 2022, The Lancet. Oncology.

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

J. Gligorov, M. Saghatchian, A. Gonçalves, 2023, Oncogene.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

J. Grenier, G. MacGrogan, G. MacGrogan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

A. Makris, S. Kuemmel, P. Schmid, 2019, JAMA oncology.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

A. Vincent-Salomon, J. Lemonnier, J. Canon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

J. Lemonnier, M. Campone, D. Cameron, 2021 .

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

J. Pignon, M. Ducreux, T. Greten, 2014, The Lancet. Oncology.

Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.

M. Mathieu, F. André, J. Soria, 2007, Anticancer research.

Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

A. Makris, S. Kuemmel, P. Schmid, 2016 .

PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207).

J. Lemonnier, B. Thürlimann, H. Hawle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

I. Sobhani, S. Culine, D. Pouessel, 2011, Oncology.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Journal of Cancer Science & Therapy Palbociclib Associated with Endocrine Therapy in Patients with Metastatic Breast Cancer: Predictive Factors of Severe Early Hematological Toxicity

J. Rossi, A. Arnaud, J. Grenier, 2019 .

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].

J. Soria, J. Grenier, 2007, Bulletin du cancer.

Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features.

P. Validire, F. Penault-Llorca, J. Soria, 2005, Lung cancer.

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study

F. Clatot, J. Ferrero, I. Moullet, 2020, Breast.

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

F. Penault-Llorca, F. André, J. Lemonnier, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.

J. Lemonnier, F. Bidard, B. Pistilli, 2018 .

[Management of biliary tract carcinomas].

A. Luciani, P. Piedbois, A. Laurent, 2009, La Revue du praticien.

Abstract PD2-06: CirculatingESR1mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

I. Bièche, J. Lemonnier, F. Bidard, 2019, Poster Discussion Abstracts.

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

J. Lemonnier, B. Thürlimann, H. Hawle, 2023, JAMA oncology.

Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer

A. Arnaud, P. Debourdeau, J. Grenier, 2020, Supportive Care in Cancer.

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

F. Bidard, N. Dohollou, S. Ladoire, 2023, Scientific reports.

[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]

A. Arnaud, P. Debourdeau, J. Grenier, 2021, Bulletin du cancer.